Xilio Therapeutics (XLO) Net Margin (2024 - 2026)

Xilio Therapeutics (XLO) has 3 years of Net Margin data on file, last reported at 111.73% in Q1 2026.

• For the quarter ending Q1 2026, Net Margin rose 36302.0% year-over-year to 111.73%; the trailing twelve-month figure through Mar 2026 stood at 79.27% (up 54140.0% YoY), and the FY2025 full-year result was 382.53%, up 234609.0% from the prior year.
• Net Margin fell to 111.73% in Q1 2026, from 86.68% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 10.47% in Q3 2025 to a low of 806.9% in Q4 2024.
• A 3-year average of 369.59% and a median of 326.47% in 2025 frame the typical range for Net Margin.
• Across the five-year window, Net Margin soared 72022 bps in 2025 and jumped 36302 bps in 2026, its largest moves.
• Tracing XLO's Net Margin over 3 years: stood at 806.9% in 2024, then surged by 89 bps to 86.68% in 2025, then decreased by 29 bps to 111.73% in 2026.
• Business Quant data shows XLO's Net Margin at 111.73% in Q1 2026, 86.68% in Q4 2025, and 10.47% in Q3 2025.